Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis

ABSTRACT: Initial treatment of the HIV is based on the use of three drugs, two of which are nucleoside analog reverse-transcriptase inhibitors. There are three combinations of these drugs which have been approved by different guidelines, each with divergent results in terms of efficacy and safety. T...

Full description

Autores:
Alzate Angel, Juan Carlos
Duque Molina, Marcela María
García García, Héctor Iván
Tipo de recurso:
Review article
Fecha de publicación:
2017
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
spa
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/19601
Acceso en línea:
http://hdl.handle.net/10495/19601
Palabra clave:
VIH
HIV
Emtricitabina
Emtricitabine
Tenofovir
Zidovudina
Zidovudine
Combinación de Medicamentos
Drug Combinations
Revisión Sistemática
Systematic Review
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id UDEA2_7c81799a0b1283b920b12951e0019b3f
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/19601
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
dc.title.translated.spa.fl_str_mv Zidovudina/Lamivudina vs Abacavir/Lamivudina vs Tenofovir/Emtricitabina en combinaciones de dosis fija como tratamiento inicial en pacientes con VIH: revisión sistemática y metanálisis en red
title Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
spellingShingle Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
VIH
HIV
Emtricitabina
Emtricitabine
Tenofovir
Zidovudina
Zidovudine
Combinación de Medicamentos
Drug Combinations
Revisión Sistemática
Systematic Review
title_short Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
title_full Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
title_fullStr Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
title_full_unstemmed Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
title_sort Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
dc.creator.fl_str_mv Alzate Angel, Juan Carlos
Duque Molina, Marcela María
García García, Héctor Iván
dc.contributor.author.none.fl_str_mv Alzate Angel, Juan Carlos
Duque Molina, Marcela María
García García, Héctor Iván
dc.contributor.researchgroup.spa.fl_str_mv Grupo Académico de Epidemiología Clínica
dc.subject.decs.none.fl_str_mv VIH
HIV
Emtricitabina
Emtricitabine
Tenofovir
Zidovudina
Zidovudine
Combinación de Medicamentos
Drug Combinations
Revisión Sistemática
Systematic Review
topic VIH
HIV
Emtricitabina
Emtricitabine
Tenofovir
Zidovudina
Zidovudine
Combinación de Medicamentos
Drug Combinations
Revisión Sistemática
Systematic Review
description ABSTRACT: Initial treatment of the HIV is based on the use of three drugs, two of which are nucleoside analog reverse-transcriptase inhibitors. There are three combinations of these drugs which have been approved by different guidelines, each with divergent results in terms of efficacy and safety. To compare the efficacy and safety of these three combinations. Systematic review and network meta-analysis of randomized clinical trials comparing fixed doses of Tenofovir Disoproxil Fumarate / Emtricitabine (TDF/FTC), Abacavir / Lamivudine (ABC/3TC) and Zidovudine / Lamivudine (ZDV/3TC). Seven clinical trials met the eligibility criteria. The results suggested higher efficacy with TDF/FTC vs. ABC/3TC at 96 weeks and vs. ZDV/3TC at 48 weeks. However, there is clinical and statistical heterogeneity. Subgroup analysis were performed by third drug and by level of viral load prior to treatment, and found no differences in virological control. Network meta-analysis could only be carried out with TDF/FTC vs. ZDV/3TC, and the proportion of patients with virological response, with no differences at 48 weeks nor at 96 weeks. Direct comparisons showed an increased risk of bone marrow suppression of ZDV/3TC vs. TDF/FTC and of ABC/3TC hypersensitivity reactions vs. ZDV/3TC. The results did not show differences in effectiveness among the interventions. However, due to the heterogeneity of the third drug and the follow-up time between the included studies, this result is not definitive. The results raise the need for further studies to help improve treatment recommendations in patients infected with HIV.
publishDate 2017
dc.date.issued.none.fl_str_mv 2017
dc.date.accessioned.none.fl_str_mv 2021-05-14T15:44:18Z
dc.date.available.none.fl_str_mv 2021-05-14T15:44:18Z
dc.type.spa.fl_str_mv Artículo de revisión
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_dcae04bc
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ARTREV
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_dcae04bc
status_str publishedVersion
dc.identifier.issn.none.fl_str_mv 1657-9534
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10495/19601
dc.identifier.doi.none.fl_str_mv 10.25100/cm.v48i2.2774
dc.identifier.eissn.none.fl_str_mv 1657-9534
identifier_str_mv 1657-9534
10.25100/cm.v48i2.2774
url http://hdl.handle.net/10495/19601
dc.language.iso.spa.fl_str_mv eng
spa
language eng
spa
dc.relation.ispartofjournalabbrev.spa.fl_str_mv Colomb Med
dc.relation.citationendpage.spa.fl_str_mv 81
dc.relation.citationissue.spa.fl_str_mv 2
dc.relation.citationstartpage.spa.fl_str_mv 70
dc.relation.citationvolume.spa.fl_str_mv 48
dc.relation.ispartofjournal.spa.fl_str_mv Colombia Médica
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
https://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 12
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad del Valle, Facultad de Salud
dc.publisher.place.spa.fl_str_mv Cali, Colombia
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/ac1045c9-f5ff-4bc1-9436-adbcf0f2ac28/download
https://bibliotecadigital.udea.edu.co/bitstreams/c34f0b27-3b81-4c56-ac77-15cea74d05e3/download
https://bibliotecadigital.udea.edu.co/bitstreams/b8898aba-2477-44a6-8546-604e6b4be7eb/download
https://bibliotecadigital.udea.edu.co/bitstreams/74240ef1-822b-4c67-a251-108a58919d47/download
https://bibliotecadigital.udea.edu.co/bitstreams/cedd87e7-c83d-4ef9-9a9c-f8621f4b9540/download
https://bibliotecadigital.udea.edu.co/bitstreams/1b60f3ac-bf1c-4fbe-b0cf-179b8d565b40/download
https://bibliotecadigital.udea.edu.co/bitstreams/3b7626ec-fe72-432d-a864-57f2ed19f438/download
https://bibliotecadigital.udea.edu.co/bitstreams/3c001233-fbaa-46cb-86a3-692d4fb549f4/download
bitstream.checksum.fl_str_mv b88b088d9957e670ce3b3fbe2eedbc13
8a4605be74aa9ea9d79846c1fba20a33
b7578d2c28c0b1a3dc41003a8c1a0d66
914b795742803f64784adc92f8a2bbb2
562add88c4e6b35540c742fe684eec6c
97319388bdee42532caee833b33becdc
a24bf58fcb9d741d8988bdef48157e73
fb235dd032768d776d83912fa72fa35a
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052590326874112
spelling Alzate Angel, Juan CarlosDuque Molina, Marcela MaríaGarcía García, Héctor IvánGrupo Académico de Epidemiología Clínica2021-05-14T15:44:18Z2021-05-14T15:44:18Z20171657-9534http://hdl.handle.net/10495/1960110.25100/cm.v48i2.27741657-9534ABSTRACT: Initial treatment of the HIV is based on the use of three drugs, two of which are nucleoside analog reverse-transcriptase inhibitors. There are three combinations of these drugs which have been approved by different guidelines, each with divergent results in terms of efficacy and safety. To compare the efficacy and safety of these three combinations. Systematic review and network meta-analysis of randomized clinical trials comparing fixed doses of Tenofovir Disoproxil Fumarate / Emtricitabine (TDF/FTC), Abacavir / Lamivudine (ABC/3TC) and Zidovudine / Lamivudine (ZDV/3TC). Seven clinical trials met the eligibility criteria. The results suggested higher efficacy with TDF/FTC vs. ABC/3TC at 96 weeks and vs. ZDV/3TC at 48 weeks. However, there is clinical and statistical heterogeneity. Subgroup analysis were performed by third drug and by level of viral load prior to treatment, and found no differences in virological control. Network meta-analysis could only be carried out with TDF/FTC vs. ZDV/3TC, and the proportion of patients with virological response, with no differences at 48 weeks nor at 96 weeks. Direct comparisons showed an increased risk of bone marrow suppression of ZDV/3TC vs. TDF/FTC and of ABC/3TC hypersensitivity reactions vs. ZDV/3TC. The results did not show differences in effectiveness among the interventions. However, due to the heterogeneity of the third drug and the follow-up time between the included studies, this result is not definitive. The results raise the need for further studies to help improve treatment recommendations in patients infected with HIV.RESUMEN: El tratamiento inicial de la infección por VIH se basa en el uso de tres medicamentos, dos de ellos inhibidores de transcriptasa reversa análogos de nucleósido. Existen tres combinaciones de estos medicamentos aprobadas por diferentes guías, con resultados divergentes en cuanto a eficacia y seguridad. Comparar la eficacia y seguridad de las 3 combinaciones. Revisión sistemática y metanálisis en red de ensayos clínicos con asignación aleatoria comparando dosis fijas de Tenofovir Disoproxil Fumarato/Emtricitabina (TDF/FTC), Abacavir/Lamivudina (ABC/3TC) y Zidovudina/Lamivudina (ZDV/3TC). Siete ensayos clínicos cumplieron los criterios de elegibilidad. Los resultados sugirieron mayor eficacia con TDF/FTC vs ABC/3TC a 96 semanas y vs. ZDV/3TC a 48 semanas. Sin embargo, existe heterogeneidad clínica y estadística. Se realizó análisis de subgrupos por tercer medicamento y por nivel de carga viral previa al tratamiento, sin encontrar diferencias en control virológico. Se pudo realizar metanálisis en red con TDF/FTC vs ZDV/3TC y proporción de pacientes con respuesta virológica, sin diferencias a las 48 semanas ni 96 semanas. Las comparaciones directas evidenciaron mayor riesgo de supresión de médula ósea de ZDV/3TC vs TDF/FTC y de reacciones de hipersensibilidad de ABC/3TC vs ZDV/3TC. Los resultados no demostraron diferencias en efectividad entre las intervenciones; sin embargo, debido a heterogeneidad en cuanto al tercer medicamento y el tiempo de seguimiento entre los estudios incluidos, dicho resultado no es definitivo. Los resultados plantean la necesidad de realizar nuevos estudios que ayuden a mejorar las recomendaciones de tratamiento en los pacientes infectados por el VIH.COL000712112application/pdfengspaUniversidad del Valle, Facultad de SaludCali, Colombiahttp://creativecommons.org/licenses/by-nc-nd/2.5/co/https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysisZidovudina/Lamivudina vs Abacavir/Lamivudina vs Tenofovir/Emtricitabina en combinaciones de dosis fija como tratamiento inicial en pacientes con VIH: revisión sistemática y metanálisis en redArtículo de revisiónhttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionVIHHIVEmtricitabinaEmtricitabineTenofovirZidovudinaZidovudineCombinación de MedicamentosDrug CombinationsRevisión SistemáticaSystematic ReviewColomb Med8127048Colombia MédicaPublicationCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstreams/ac1045c9-f5ff-4bc1-9436-adbcf0f2ac28/downloadb88b088d9957e670ce3b3fbe2eedbc13MD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/c34f0b27-3b81-4c56-ac77-15cea74d05e3/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADORIGINALDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdfDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdfArtículo de revisión - Inglésapplication/pdf1418509https://bibliotecadigital.udea.edu.co/bitstreams/b8898aba-2477-44a6-8546-604e6b4be7eb/downloadb7578d2c28c0b1a3dc41003a8c1a0d66MD51trueAnonymousREADDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdfDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdfArtículo de revisión - Españolapplication/pdf1407249https://bibliotecadigital.udea.edu.co/bitstreams/74240ef1-822b-4c67-a251-108a58919d47/download914b795742803f64784adc92f8a2bbb2MD54falseAnonymousREADTEXTDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdf.txtDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdf.txtExtracted texttext/plain56337https://bibliotecadigital.udea.edu.co/bitstreams/cedd87e7-c83d-4ef9-9a9c-f8621f4b9540/download562add88c4e6b35540c742fe684eec6cMD55falseAnonymousREADDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdf.txtDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdf.txtExtracted texttext/plain59237https://bibliotecadigital.udea.edu.co/bitstreams/1b60f3ac-bf1c-4fbe-b0cf-179b8d565b40/download97319388bdee42532caee833b33becdcMD57falseAnonymousREADTHUMBNAILDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdf.jpgDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdf.jpgGenerated Thumbnailimage/jpeg15611https://bibliotecadigital.udea.edu.co/bitstreams/3b7626ec-fe72-432d-a864-57f2ed19f438/downloada24bf58fcb9d741d8988bdef48157e73MD56falseAnonymousREADDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdf.jpgDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdf.jpgGenerated Thumbnailimage/jpeg15503https://bibliotecadigital.udea.edu.co/bitstreams/3c001233-fbaa-46cb-86a3-692d4fb549f4/downloadfb235dd032768d776d83912fa72fa35aMD58falseAnonymousREAD10495/19601oai:bibliotecadigital.udea.edu.co:10495/196012025-03-27 00:44:03.12http://creativecommons.org/licenses/by-nc-nd/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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